Pharmasset Announces Intent To Amend QUANTUM Trial
This can be looked at as a slight negative for VRUS IMO and terrible news for the other developers of purine nucleotide analogs.
The bad news
VRUS/GILD lost the only drug in the pipeline they could fall back on.
The good news (for VRUS/GILD)
INHX and IDIX are both developing purine based nucleotides like PSI-938 and this doesn't bode well for INX-189 and IDX-184 which is already on a partial clinical hold.
How many developers other than VRUS are working on pyrimidine nucleotides? Alios might have one in pre-clinical or phase 1 testing. Roche has RG7128 which they licensed from VRUS.
This may only enhance the lead VRUS/GILD have in all-oral therapy. Dew was right. PSI-938 wasn't worth 3 out of the 11 billion GILD is paying for VRUS after-all.
Market Data 
Markets 
AI
